HEALTH PROFESSIONAL · SOURCE READING
Limb-sparing procedures
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
In general, more than 80% of patients with extremity osteosarcoma can be treated using a limb-sparing procedure and do not require amputation.[8] Limb-sparing procedures are planned only when the preoperative staging indicates that it would be possible to achieve wide surgical margins. In one study, patients who underwent limb-salvage procedures who had poor histological response and close surgical margins had a high rate of local recurrence.[9]
Reconstruction after limb-sparing surgery can be accomplished with many options, including metallic endoprosthesis, allograft, vascularized autologous bone graft, and rotationplasty. An additional option, osteogenesis distraction bone transport, is available for patients whose tumors do not involve the epiphysis of long bones.[10] This procedure results in a stable reconstruction that functionally restores the normal limb.
Source links and citations
The choice of optimal surgical reconstruction involves many factors, including the following:[11][Level of evidence A1]
Source links and citations
Site and size of the primary tumor.
Ability to preserve the neurovascular supply of the distal extremity.
Age of the patient and potential for additional growth.
Needs and desires of the patient and family for specific functions such as sports participation.
If a complicated reconstruction delays or prohibits the resumption of systemic chemotherapy, limb preservation may endanger the chance for cure. In retrospective analyses of 703 patients with localized osteosarcoma, the resumption of chemotherapy 21 days or more after definitive surgery was associated with an increased risk of death and adverse events (hazard ratio [HR], 1.57; 1.04–2.36).[11] Delays in total time to completion of chemotherapy have also been associated with inferior OS and event-free survival (EFS). In a retrospective multivariate analysis of 113 patients with localized osteosarcoma, a delay of time to completion of chemotherapy greater than 4 weeks was associated with an OS HR of 2.70 (1.11–6.76, P = .003) and an EFS HR of 1.13 (1.00–1.26, P = .016).[12]
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice
Triangle